Cargando…

Effect of PKC-β Signaling Pathway on Expression of MCP-1 and VCAM-1 in Different Cell Models in Response to Advanced Glycation End Products (AGEs)

Advanced glycation end products (AGEs) are compounds classified as uremic toxins in patients with chronic kidney disease that have several pro-inflammatory effects and are implicated in the development of cardiovascular diseases. To explore the mechanisms of AGEs–endothelium interactions through the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rempel, Lisienny C. T., Finco, Alessandra B., Maciel, Rayana A. P., Bosquetti, Bruna, Alvarenga, Larissa M., Souza, Wesley M., Pecoits-Filho, Roberto, Stinghen, Andréa E. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448170/
https://www.ncbi.nlm.nih.gov/pubmed/26008233
http://dx.doi.org/10.3390/toxins7051722
_version_ 1782373664609533952
author Rempel, Lisienny C. T.
Finco, Alessandra B.
Maciel, Rayana A. P.
Bosquetti, Bruna
Alvarenga, Larissa M.
Souza, Wesley M.
Pecoits-Filho, Roberto
Stinghen, Andréa E. M.
author_facet Rempel, Lisienny C. T.
Finco, Alessandra B.
Maciel, Rayana A. P.
Bosquetti, Bruna
Alvarenga, Larissa M.
Souza, Wesley M.
Pecoits-Filho, Roberto
Stinghen, Andréa E. M.
author_sort Rempel, Lisienny C. T.
collection PubMed
description Advanced glycation end products (AGEs) are compounds classified as uremic toxins in patients with chronic kidney disease that have several pro-inflammatory effects and are implicated in the development of cardiovascular diseases. To explore the mechanisms of AGEs–endothelium interactions through the receptor for AGEs (RAGE) in the PKC-β pathway, we evaluated the production of MCP-1 and VCAM-1 in human endothelial cells (HUVECs), monocytes, and a coculture of both. AGEs were prepared by albumin glycation and characterized by absorbance and electrophoresis. The effect of AGEs on cell viability was assessed with an MTT assay. The cells were also treated with AGEs with and without a PKC-β inhibitor. MCP-1 and VCAM-1 in the cell supernatants were estimated by ELISA, and RAGE was evaluated by immunocytochemistry. AGEs exposure did not affect cell viability, but AGEs induced RAGE, MCP-1, and VCAM-1 expression in HUVECs. When HUVECs or monocytes were incubated with AGEs and a PKC-β inhibitor, MCP-1 and VCAM-1 expression significantly decreased. However, in the coculture, exposure to AGEs and a PKC-β inhibitor produced no significant effect. This study demonstrates, in vitro, the regulatory mechanisms involved in MCP-1 production in three cellular models and VCAM-1 production in HUVECs, and thus mimics the endothelial dysfunction caused by AGEs in early atherosclerosis. Such mechanisms could serve as therapeutic targets to reduce the harmful effects of AGEs in patients with chronic kidney disease.
format Online
Article
Text
id pubmed-4448170
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44481702015-06-01 Effect of PKC-β Signaling Pathway on Expression of MCP-1 and VCAM-1 in Different Cell Models in Response to Advanced Glycation End Products (AGEs) Rempel, Lisienny C. T. Finco, Alessandra B. Maciel, Rayana A. P. Bosquetti, Bruna Alvarenga, Larissa M. Souza, Wesley M. Pecoits-Filho, Roberto Stinghen, Andréa E. M. Toxins (Basel) Article Advanced glycation end products (AGEs) are compounds classified as uremic toxins in patients with chronic kidney disease that have several pro-inflammatory effects and are implicated in the development of cardiovascular diseases. To explore the mechanisms of AGEs–endothelium interactions through the receptor for AGEs (RAGE) in the PKC-β pathway, we evaluated the production of MCP-1 and VCAM-1 in human endothelial cells (HUVECs), monocytes, and a coculture of both. AGEs were prepared by albumin glycation and characterized by absorbance and electrophoresis. The effect of AGEs on cell viability was assessed with an MTT assay. The cells were also treated with AGEs with and without a PKC-β inhibitor. MCP-1 and VCAM-1 in the cell supernatants were estimated by ELISA, and RAGE was evaluated by immunocytochemistry. AGEs exposure did not affect cell viability, but AGEs induced RAGE, MCP-1, and VCAM-1 expression in HUVECs. When HUVECs or monocytes were incubated with AGEs and a PKC-β inhibitor, MCP-1 and VCAM-1 expression significantly decreased. However, in the coculture, exposure to AGEs and a PKC-β inhibitor produced no significant effect. This study demonstrates, in vitro, the regulatory mechanisms involved in MCP-1 production in three cellular models and VCAM-1 production in HUVECs, and thus mimics the endothelial dysfunction caused by AGEs in early atherosclerosis. Such mechanisms could serve as therapeutic targets to reduce the harmful effects of AGEs in patients with chronic kidney disease. MDPI 2015-05-14 /pmc/articles/PMC4448170/ /pubmed/26008233 http://dx.doi.org/10.3390/toxins7051722 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rempel, Lisienny C. T.
Finco, Alessandra B.
Maciel, Rayana A. P.
Bosquetti, Bruna
Alvarenga, Larissa M.
Souza, Wesley M.
Pecoits-Filho, Roberto
Stinghen, Andréa E. M.
Effect of PKC-β Signaling Pathway on Expression of MCP-1 and VCAM-1 in Different Cell Models in Response to Advanced Glycation End Products (AGEs)
title Effect of PKC-β Signaling Pathway on Expression of MCP-1 and VCAM-1 in Different Cell Models in Response to Advanced Glycation End Products (AGEs)
title_full Effect of PKC-β Signaling Pathway on Expression of MCP-1 and VCAM-1 in Different Cell Models in Response to Advanced Glycation End Products (AGEs)
title_fullStr Effect of PKC-β Signaling Pathway on Expression of MCP-1 and VCAM-1 in Different Cell Models in Response to Advanced Glycation End Products (AGEs)
title_full_unstemmed Effect of PKC-β Signaling Pathway on Expression of MCP-1 and VCAM-1 in Different Cell Models in Response to Advanced Glycation End Products (AGEs)
title_short Effect of PKC-β Signaling Pathway on Expression of MCP-1 and VCAM-1 in Different Cell Models in Response to Advanced Glycation End Products (AGEs)
title_sort effect of pkc-β signaling pathway on expression of mcp-1 and vcam-1 in different cell models in response to advanced glycation end products (ages)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448170/
https://www.ncbi.nlm.nih.gov/pubmed/26008233
http://dx.doi.org/10.3390/toxins7051722
work_keys_str_mv AT rempellisiennyct effectofpkcbsignalingpathwayonexpressionofmcp1andvcam1indifferentcellmodelsinresponsetoadvancedglycationendproductsages
AT fincoalessandrab effectofpkcbsignalingpathwayonexpressionofmcp1andvcam1indifferentcellmodelsinresponsetoadvancedglycationendproductsages
AT macielrayanaap effectofpkcbsignalingpathwayonexpressionofmcp1andvcam1indifferentcellmodelsinresponsetoadvancedglycationendproductsages
AT bosquettibruna effectofpkcbsignalingpathwayonexpressionofmcp1andvcam1indifferentcellmodelsinresponsetoadvancedglycationendproductsages
AT alvarengalarissam effectofpkcbsignalingpathwayonexpressionofmcp1andvcam1indifferentcellmodelsinresponsetoadvancedglycationendproductsages
AT souzawesleym effectofpkcbsignalingpathwayonexpressionofmcp1andvcam1indifferentcellmodelsinresponsetoadvancedglycationendproductsages
AT pecoitsfilhoroberto effectofpkcbsignalingpathwayonexpressionofmcp1andvcam1indifferentcellmodelsinresponsetoadvancedglycationendproductsages
AT stinghenandreaem effectofpkcbsignalingpathwayonexpressionofmcp1andvcam1indifferentcellmodelsinresponsetoadvancedglycationendproductsages